Embracing enforcement and examinations – Asia-Pacific IP Focus launched

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Embracing enforcement and examinations – Asia-Pacific IP Focus launched

editorial-adobestock-440916445.jpg

IP experts have come together in Asia-Pacific IP Focus to provide insight into IP developments for 2021 and beyond.

Managing IP’s 2021 Asia-Pacific IP Focus looks at a series of thought-provoking IP developments across China, India, Japan and South Korea, that have come to the forefront during the past few months.

Interaction with national patent offices is a seminal topic in this guide, as countries respond to the increasing use of enforcement and examinations, while contending with how to react to the changes under IP law.

In June 2021, China’s amended patent law came into force, with notable wider protection offered for designs. Through the use of case studies, the article by DEQI Intellectual Property explains how applicants can overcome office actions concerning substantive defects of design applications.

Arguments for inventive step in the Japan Patent Office examination can be categorised into five particular groups: fact finding, matter of design, motivation, obstructive factor and effect. If an applicant can persuade the examiner to accept any one of these arguments, the rejection of inventive step is overturned. Shiga International Patent Office’s article presents a statistical analysis of the effectiveness of such arguments in the examination.

The Indian Patent Office has often been seen to interpret Section 59 of the Indian Patent Act in a highly restrictive manner, thus raising barriers to amendment. The authors from Anand and Anand explore the limits of claim amendments in India and call for modification to the rules to reflect global standards.

Through a set of example cases, FirstLaw PC’s article outlines the investigation procedure that can be sought by IP holders against unfair international trade practices involving IP infringement through the Korea Trade Commission’s proceedings. Corrective measures, penalties and remedies for such infringement are cited in further detail.

As the investment climate bounces back in the Asia-Pacific, IP queries and research and development looks set to grow in the coming year. We hope that you enjoy hearing from the IP experts leading the progression in our Asia-Pacific IP Focus.

Prin Shasiharan

Senior commercial editor

Managing IP

Click here to read all the chapters from Asia-Pacific IP Focus 2021

more from across site and SHARED ros bottom lb

More from across our site

Benjamin Kelly, the firm’s fifth IP partner hire in a little over one year, has experience in patent and trade secret disputes involving complex technologies
Half-year Talent Tracker data shows Pierson Ferdinand was among the most prolific hirers in the US, while in Europe, there has been a notable UPC swing
Exclusive data reveals in-house counsel want external legal advisers to build better client relationships and add value beyond routine work
Brett Sandford acted for Perplexity AI, which fended off the threat of a preliminary injunction to launch an AI-powered web browser
Stephen Yang joins us for our ‘Five minutes with’ series to explain why his role requires him to wear many hats
The complaint follows a declaratory ruling issued by the England and Wales High Court last month that said Samsung is entitled to an interim licence
Tobias Hahn explains how the firm's multi-jurisdictional setup enabled it to secure an injunction on behalf of Fujifilm relating to defendant Kodak’s non-UPC activity
Reckitt Benckiser is to divest its Essential Home business, which includes more than 70 brands, to private equity firm Advent International
Litigator Neel Chatterjee, who has joined the firm as a co-leader of the IP team, reveals tech ambitions and expansion plans
A settlement between Philips and Transsion and a loss for AstraZeneca in the UK were also among the top talking points
Gift this article